Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 1
2011 3
2012 7
2013 9
2014 13
2015 13
2016 15
2017 44
2018 50
2019 71
2020 51
2021 56
2022 78
2023 80
2024 36

Text availability

Article attribute

Article type

Publication date

Search Results

447 results

Results by year

Filters applied: . Clear all
Page 1
Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group.
Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F, Leontiadis GI, Abraham NS, Calvet X, Chan FKL, Douketis J, Enns R, Gralnek IM, Jairath V, Jensen D, Lau J, Lip GYH, Loffroy R, Maluf-Filho F, Meltzer AC, Reddy N, Saltzman JR, Marshall JK, Bardou M. Barkun AN, et al. Among authors: jairath v. Ann Intern Med. 2019 Dec 3;171(11):805-822. doi: 10.7326/M19-1795. Epub 2019 Oct 22. Ann Intern Med. 2019. PMID: 31634917 Free PMC article.
Vedolizumab for the Treatment of Chronic Pouchitis.
Travis S, Silverberg MS, Danese S, Gionchetti P, Löwenberg M, Jairath V, Feagan BG, Bressler B, Ferrante M, Hart A, Lindner D, Escher A, Jones S, Shen B; EARNEST Study Group. Travis S, et al. Among authors: jairath v. N Engl J Med. 2023 Mar 30;388(13):1191-1200. doi: 10.1056/NEJMoa2208450. N Engl J Med. 2023. PMID: 36988594 Clinical Trial.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Among authors: jairath v. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting.
Parigi TL, D'Amico F, Abreu MT, Dignass A, Dotan I, Magro F, Griffiths AM, Jairath V, Iacucci M, Mantzaris GJ, O'Morain C, Reinisch W, Sachar DB, Turner D, Yamamoto T, Rubin DT, Peyrin-Biroulet L, Ghosh S, Danese S. Parigi TL, et al. Among authors: jairath v. Lancet Gastroenterol Hepatol. 2023 Sep;8(9):853-859. doi: 10.1016/S2468-1253(23)00154-1. Epub 2023 Jul 6. Lancet Gastroenterol Hepatol. 2023. PMID: 37423233 Review.
Targeting IL-23 for IBD: Rationale and Progress to Date.
Vuyyuru SK, Shackelton LM, Hanzel J, Ma C, Jairath V, Feagan BG. Vuyyuru SK, et al. Among authors: jairath v. Drugs. 2023 Jul;83(10):873-891. doi: 10.1007/s40265-023-01882-9. Epub 2023 Jun 2. Drugs. 2023. PMID: 37266801 Review.
Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.
Lin SN, Mao R, Qian C, Bettenworth D, Wang J, Li J, Bruining DH, Jairath V, Feagan BG, Chen MH; Stenosis Therapy and Antifibrotic Research (STAR) Consortium; Rieder F. Lin SN, et al. Among authors: jairath v. Physiol Rev. 2022 Apr 1;102(2):605-652. doi: 10.1152/physrev.00005.2021. Epub 2021 Sep 27. Physiol Rev. 2022. PMID: 34569264 Free PMC article. Review.
447 results